Drug Profile
Research programme: multi-antibody therapy - Regeneron Pharmaceuticals
Latest Information Update: 09 May 2020
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections